Radiotherapy before versus after surgery for brain metastases
Compares focused radiation given before or after surgery in adults with brain metastases.
Key facts
- Who runs it
- GCS Ramsay Santé pour l'Enseignement et la Recherche
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases
- Status
- Not yet recruiting
- People taking part
- 68 people, planned
- Started
- Sept 2026
- Expected to end
- 30 Jun 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- stereotactic radiotherapy
- Excision surgery
- Record updated
- 25 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with 1 to 12 brain metastases (cancer spread to the brain), where at least one can be removed by surgery. It compares focused radiotherapy given before surgery with radiotherapy given after surgery.
- Age
- 18 years and older
- Sex
- All
- Disease stage
- 1 to 12 brain metastases on MRI before surgery. At least one must be at least 1 cm (0.4 in) and reachable for removal as fully as possible. Karnofsky performance score of 70 or more (able to care for yourself).
- Earlier treatment
- The target brain metastasis must not have been treated before with surgery, radiosurgery or radiotherapy.
Main reasons for not taking part
- Prior surgery, radiosurgery or radiotherapy for the target brain metastasis
- Cannot have an MRI for medical reasons
- Expected to live 3 months or less
- Taking part in another clinical trial, or in its exclusion period
- Unable to do brain function tests without help or to fill in a questionnaire alone
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients aged 18 years and older
- Patients with 1 to 12 brain metastases on preoperative MRI, at least one of which (contrast enhancement of at least 1 cm) is accessible for the most complete possible resection (target lesion)
- Patients with a Karnofsky performance score of ≥ 70
- Patients able to perform neurocognitive tests without assistance
- Patients who understand the study and agree to attend all visits
- Patients who have signed a written informed consent form
- Affiliation with a social security system
Who cannot take part
- Patient who has already been treated with surgery, radiosurgery, and/or radiotherapy for the target brain metastasis
- Medical contraindication to MRI
- Patient with an estimated life expectancy of ≤ 3 months
- Patients participating in another clinical trial, or who are in the exclusion period of another clinical trial
- Patients unable to complete a self-administered questionnaire
- Patients from a vulnerable population
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the local control rate on the target lesion at 6, 12, and 24 months after treatment with neoadjuvant stereotactic radiotherapy (SRS NEO group) compared to standard care, adjuvant stereotactic radiotherapy (POST OP SRS group).
The 2 groups in the trial
- Neoadjuvant stereotactic radiotherapyTreatment being tested
Innovative treatment with neoadjuvant stereotactic radiotherapy, with the protocol requiring SRS to be performed 4 days ± 1 day before surgery to remove the target brain metastasis. Neuronavigation magnetic resonance imaging and a tracking scan, necessary for contouring the lesions and creating the treatment mask, will be performed within 7 days prior to the start of radiotherapy. These examinations are essential regardless of the type of stereotactic radiotherapy (adjuvant or neoadjuvant) and are routinely performed for lesion contouring.
Treatment: stereotactic radiotherapy and Excision surgery
- Control group : adjuvant stereotactic radiotherapyExisting treatment, for comparison
Standard care in accordance with the gold standard, with stereotactic radiotherapy performed as an adjunct to the surgical bed of the targeted lesion, i.e., 4 to 6 weeks after surgery. Neuronavigation magnetic resonance imaging and a tracking scan, necessary for contouring the lesions and creating the treatment mask, will be performed within 7 days prior to the start of radiotherapy.
Treatment: stereotactic radiotherapy and Excision surgery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective, Randomized, Multicenter Study Comparing the Efficacy and Tolerance of Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy in the Management of Brain Metastases
- Plain-language title
- Radiotherapy before versus after surgery for brain metastasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 25 August 2026